Why was early therapeutic research on psychedelic drugs abandoned?

The paper situates itself in the recent revival of clinical research on psychedelics such as psilocybin and MDMA for conditions including depression, anxiety in terminal illness and addiction. The author notes that advocates commonly argue that mid-20th century therapeutic research on LSD and related compounds was prematurely terminated by Richard Nixon's 'War on Drugs'. Historical scholarship, however, suggests a more complex explanation involving regulatory, scientific, industrial and social factors, and that earlier advocacy for psychedelics was sometimes over‑exuberant. The study sets out to describe North American research on LSD in the 1950s and 1960s—particularly for alcohol dependence, anxiety in terminal illness, and anxiety/depression—and to analyse the constellation of factors that led to the abandonment of that research. The paper uses the broad working definition of 'psychedelic' common in the historical literature and aims to draw lessons for contemporary clinical research and policy as newer trials progress through Phase II stages and beyond.

The author conducted an analysis of historical scholarship on psychedelic research in North America during the 1950s, 1960s and 1970s. The extracted text describes a narrative synthesis of previously published historical accounts and scientific reports rather than a formal systematic review. The scope emphasised clinical investigations of LSD for alcoholism, psychodynamic uses (psycholytic therapy), and applications in terminal cancer anxiety, and examined contemporaneous regulatory, industrial and social developments that affected research. The paper reconstructs regulatory changes (notably US Food and Drug Administration requirements introduced after the Thalidomide tragedy), corporate decisions about drug supply, the outcomes of later randomised controlled trials, media and cultural influences (including prominent advocates and adverse publicity), funding changes at institutional and state levels, and the ways in which these factors interacted to influence research trajectories. The extracted text does not clearly report a formal search strategy, databases consulted, inclusion/exclusion criteria, or a risk-of-bias assessment of the historical sources used.

The author reports that multiple, interacting factors contributed to the decline of therapeutic psychedelic research rather than a single legislative cause. Key findings include: - Early clinical reports were often uncontrolled and subject to criticism. For example, Humphry Osmond and colleagues reported that 50% of alcohol-dependent patients given LSD were still abstinent 6 months after treatment, and psycholytic therapists reported around 70% improvement in uncontrolled case series for neurotic disorders. Critics argued these studies were small, poorly controlled and prone to biased outcome assessment. Later controlled trials did not consistently replicate these strong uncontrolled results; a meta-analysis of LSD for alcoholism found better outcomes at 6 months but no advantage at 12 months. - Regulatory tightening after the Thalidomide tragedy (early 1960s) changed the landscape for pharmaceutical research. New FDA requirements made 'clinical research' contingent on a Clinical Trial Notification (CTN) that included preclinical dossiers and a detailed randomised controlled trial (RCT) protocol. Very few RCTs of psychedelics had been completed before 1963, so psychedelic research was subject to these new requirements. - Practical and methodological challenges complicated RCTs of psychedelic drugs. The conspicuous psychoactive effects made double-blinding difficult because patients (and often investigators) could infer treatment allocation, undermining standard placebo-controlled designs. - Industry and supply decisions were influential. In 1965 Sandoz ceased providing LSD for general research—partly in response to reputational damage from nonmedical use and adverse media coverage—limiting availability to university-based researchers and NIH-funded projects. - The Controlled Substances Act (CSA) of 1970 increased legal and logistical barriers but did not, by itself, immediately end clinical research. The FDA and NIH continued to support and fund clinical trials into the 1970s; the State of Maryland financed a research centre that ran randomised trials until 1979. That centre eventually lost funding for reasons including interpersonal disputes, adverse publicity (e.g. reactions to a US Senate report on CIA research with LSD), and recommendations to reallocate funds to other priority areas such as schizophrenia research. - Social and cultural factors compounded scientific and regulatory difficulties. High‑profile advocacy by figures such as Timothy Leary, prevalence of nonmedical use, sensational media reports (including coverage of Charles Manson and other cult figures), and incidents of psychoses and suicide attempts associated with some therapeutic or recreational use generated public and professional alarm. Sidney Cohen and others reported adverse events that fuelled calls for tighter control. The association of psychedelics with countercultural movements and reports of misuse in contexts such as CIA programmes aggravated the drugs' reputational problems. - Pharmaceutical industry disinterest in funding large clinical trials and difficulties meeting new regulatory demands further discouraged therapeutic research. The net result was a gradual attrition of research capacity and funding that preceded and then outlasted legislative scheduling. - The author also reports contemporary developments: modern researchers have distanced themselves from countercultural advocates, have prioritised psilocybin (shorter duration and fewer cultural baggage issues than LSD) and MDMA in clinical trials, and have been conducting randomised trials that satisfy current regulatory expectations (notably Phase II studies). However, the paper notes concerns that compassionate‑use schemes and political efforts (referenda to decriminalise or legalise psychedelic mushrooms) could enable widespread use ahead of robust evidence, mirroring the trajectory observed with medical cannabis.

The author interprets the historical record as indicating that the demise of mid-20th century therapeutic psychedelic research cannot be attributed solely to Nixon's 'War on Drugs' or the 1970 Controlled Substances Act. Rather, regulatory reform prompted by the Thalidomide tragedy, methodological challenges in conducting blinded RCTs with overtly psychoactive drugs, the withdrawal of commercial supply (notably Sandoz's 1965 decision), adverse publicity and cultural opposition, interpersonal and institutional funding decisions, and pharmaceutical industry unwillingness to underwrite costly trials all acted together to curtail research. Compared with early uncontrolled enthusiasm, later controlled trials produced less uniformly positive results, which reduced scientific momentum. The author emphasises that exuberant advocacy by some early proponents contributed to suspicion within the research community and to negative public perceptions when unsupervised or nonmedical use proliferated. Contemporary researchers have sought to avoid those pitfalls by distancing themselves from earlier advocates, discouraging nonmedical use, and using more rigorous trial designs focused on compounds such as psilocybin and MDMA. The author highlights policy and implementation risks: compassionate access programmes, off‑label prescribing, and political efforts to legalise or decriminalise psychedelics could result in widespread therapeutic and nontherapeutic use ahead of definitive evidence on safety and efficacy, repeating aspects of the earlier era. The paper therefore argues for cautious reintroduction of psychedelics into psychiatric practice, with clinical use concentrated in supervised research and teaching settings to minimise the risk of repeating past social and clinical harms. The extracted text does not provide a formal limitations section describing constraints of the present historical analysis (for example, detailing source selection or potential bias in secondary accounts), so the scope and methods of the historical synthesis are not fully specified in the extracted material.

The author concludes that the history of psychiatric research on psychedelic drugs is complex and not reducible to a single cause such as the 'War on Drugs'. Multiple interacting factors—regulatory tightening, methodological challenges for controlled trials, withdrawal of industry support, adverse publicity and cultural dynamics—collectively led to the abandonment of much early therapeutic research. This history counsels caution: clinical use should be restricted to supervised research and teaching settings to mitigate the risks of unsupervised, widespread adoption, especially in light of contemporary pressures such as compassionate‑use schemes and political moves to decriminalise or legalise psychedelic plants.